Frontiers39m
Early Phase Clinical Trials for the Development of Novel Immunotherapeutic Anti-cancer Agents
Drug development in oncology is historically challenging, exhibiting a very high attrition rate, with low rates of approval for novel treatments when compared to other therapeutic areas. At present, ...
MassDevice15h
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment
Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung ...
Morgan Stanley and Cisco Shine, S&P 500 Eyes Rebound in Today’s Trading
S&P 500 and Nasdaq 100 futures steady amid tech losses. Morgan Stanley beats Q3 estimates, up 3%, and Cisco climbs 2% on AI ...
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
BioWorld1d
Novocure’s tumor treating fields land FDA approval for lung cancer
Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
NovoCure’s Growth Potential Boosted by FDA Approval and Market Expansion
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
Stocks to Watch Wednesday: ASML, Intel, Abbott, LVMH
Louis Vuitton owner LVMH reported disappointing results and said it faced challenges in most markets. Shares of both the ...
The American Journal of Managed Care1d
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
FierceBiotech1d
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Targeted Oncology1d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...